Teleflex Incorporated (TFX) Q3 2024 Earnings Call Transcript Summary
Teleflex Incorporated (TFX) Q3 2024 Earnings Call Transcript Summary
Adjusted operating margin was slightly improved by 10 basis points year-over-year at 27.3%.The following is a summary of the Teleflex Incorporated (TFX) Q3 2024 Earnings Call Transcript:
以下是泰利福公司(TFX)2024年第三季度業績電話會議記錄摘要:
Financial Performance:
金融業績：
Revenues for Q3 were $764.4 million, marking a 2.4% increase year-over-year on a GAAP basis, and a 2.2% increase on an adjusted constant currency basis.
Adjusted gross margin was 60.8% for the quarter, up 140 basis points from the prior year, mainly due to the favorable impact of gross margin from the termination of the MSA and the acquisition of Palette, offset by manufacturing inefficiencies and continued cost inflation.
Adjusted operating margin was slightly improved by 10 basis points year-over-year at 27.3%.
Adjusted earnings per share was $3.49, a decrease of 4.1% compared to last year, impacted by the acquisition-related costs, including Palette Life Sciences and a higher tax rate.
第三季度營收爲76440萬美元，按照美國通用會計準則計算，同比增長2.4%，按照調整後的固定貨幣基礎計算，增長2.2%。
本季度調整後的毛利率爲60.8%，比去年同期增加了140個點子，主要由於終止Msa以及收購Palette對毛利率的有利影響，抵消了製造效率低下和持續成本通脹。
調整後的營業利潤率同比略有改善，爲27.3%，提高了10個點子。
調整後的每股收益爲3.49美元，較去年下降了4.1%，受收購相關成本影響，包括Palette Life Sciences和較高的稅率。
Business Progress:
業務進展：
Expanded clinical data supporting the use of the Titan SGS stapler in bariatric surgery, showing improved outcomes and efficiency.
Continued market penetration of MANTA in TAVR and EVAR procedures, benefitting from less price sensitivity in EVAR.
Growing traction of Barrigel in the U.S. following the acquisition of Palette Life Sciences, with planned studies to expand indications.
Increase in manufacturing capacity for intra-aortic balloon pumps and catheters to meet rising demand.
擴展的臨床數據支持Titan SGS釘曲器在肥胖手術中的使用，顯示出改善的效果和效率。
在TAVR和EVAR手術中，MANTA的市場滲透持續增加，受益於EVAR手術對價格敏感性降低。
在Palette Life Sciences收購後，Barrigel在美國的市場佔有率不斷增長，計劃進行研究以擴大適應症。
增加主動脈球囊泵和導管的製造能力，以滿足不斷增長的需求。
Opportunities:
機會：
Market Expansion: Continued strategy to increase the geographic availability of Teleflex products, improving Europe utilization.
Product Innovation: Execution of strategy to expand usage of global PICC and Barrigel products.
Strategic Partnerships: Potential market opportunities from increased adoption of intra-aortic balloon pumps following FDA recommendations.
市場擴張：繼續執行擴大泰利福產品地理可用性的策略，提高歐洲的利用率。
產品創新：執行全球PICC和Barrigel產品擴大使用規模的策略。
戰略合作伙伴關係：隨着FDA的建議增加導管球囊泵的採用率，有潛在的市場機會。
Risks:
風險：
Operational Disruptions: Soft performance in OEM business and unexpected vertical integration of component by a major customer leading to revenue loss.
Economic Fluctuations: Impact from the ongoing doctor strike in South Korea affecting APAC growth and market competition from new intraosseous device competitor.
Financial Market Volatility: Impact from increased net interest expense due to funding for the acquisition of Palette and share repurchases.
運營中斷：OEm業務表現疲軟，加上一大客戶意外縱向整合零部件導致營收損失。
經濟波動：韓國醫生罷工持續影響亞太地區增長，新的骨內穿設備競爭對手還帶來市場競爭。
金融市場波動：受淨利息支出增加的影響，這是由於爲收購Palette和回購股份籌資。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
